NRBO - NeuroBo Pharmaceuticals EPS misses by $0.02

NeuroBo Pharmaceuticals (NRBO): Q3 GAAP EPS of -$0.19 misses by $0.02.Cash and equivalents were $12.4M as of Sep. 30, 2020, compared with $13.9M at Dec. 31, 2019; expects that its cash position will be adequate to fund operations into 3Q21."Given the global resurgence of COVID-19, we have postponed continued work on the IND and the first human clinical trials for NB-02 until global health and macroeconomic conditions improve, with a view toward commencing clinical trial activity in 2H21," president & CEO Richard J. Kang, Ph.D. commented.Press Release

For further details see:

NeuroBo Pharmaceuticals EPS misses by $0.02